Jack Bui, M.D., Ph.D.

Jack Bui, M.D., Ph.D.

  • Associate Professor
  • Director of the Stem Cell Processing Laboratory
  • Director of Flow Cytometry
  • Director of Diagnostic Immunology
  • M.D. - University of California, San Diego
  • Ph.D. - University of California, San Diego
  • Residency Training: Washington University / Barnes Jewish Hospital
  • Board Certifications: Clinical Pathology
  • Clinical Specialty: Immune Function Tests

Research Interests

Our laboratory is interested in how the innate immune system recognizes developing tumor cells. Toward this end, we have generated a bank of tumor cell lines which we believe are enriched in recognition structures that activate innate immune components, including natural killer (NK) cells and macrophages. We hope to understand the molecular basis of this recognition.

We also have focused on a family of ligands for the NK cell receptor NKG2D. These NKG2D ligands are highly expressed on tumors, virally infected cells, and in certain autoimmune diseased tissues. We have shown that the NKG2D ligand H60 is regulated by the interferons and may function in this aspect to modulate the immune system. We are actively pursuing the regulation of H60 during carcinogenesis in order to understand how recognition structures might be acquired during the transformation process.

A related interest is in how T-regulatory cells inhibit the immune response to tumors. We have shown that these cells accumulate in both progressively growing and rejecting tumors. We plan to identify the mechanisms by which T-regulatory cells become activated in certain tumors for clinical benefit.
Click here for information on the Bui Lab.

Representative Publications

  1. Buchau, A., Morizane, S., Trowbridge, J., Schauber, J., Kotol, P., Bui, J.D., and Gallo, R.L. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. Journal of Immunology 2010; 184(1):369-78.
  2. Yadav, D., Ngolab, J., Lim, R., Krishnamurthy, S., Bui, J.D. Down-regulation of major histocompatibility complex class I-related chain A (MICA) on tumor cells by IFN╬│-induced microRNA. Journal of Immunology 2009; 182 (1): 39-43.
  3. Bui, J.D. and Schreiber, R.D. Cancer Immunosurveillance, immunoediting, and inflammation : Independent or interdependent processes? Current Opinion in Immunology. 2007, 19(2):203-8.
  4. Bui, J.D., Uppaluri, R., Hsieh, C., and Schreiber, R.D. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006 Jul 15;66(14):7301-9.
  5. Click here to search for my publications


Jack Bui received his undergraduate degree in Biochemistry at the University of California, Berkeley and his M.D. and Ph.D. degrees from the University of California, San Diego. He then trained as a clinical pathology resident at Washington University in St. Louis, where he also worked as a post-doctoral fellow on innate immunity and cancer. As a graduate student, Dr. Bui was first author on thesis research that was published in Cell. In this paper, Dr. Bui demonstrated the important role of calcium/calmodulin kinase II in the development of antigen-dependent memory T cells. His work subsequently turned to the specific problem of cancer recognition by the immune system. In pursuing this issue, Dr. Bui has examined the regulation of recognition structures on mouse tumors and has generated a panel of novel cell lines that may be well recognized by the innate immune system. Dr. Bui joined the faculty at UCSD in August, 2006. He interfaces between the established cancer research program and our growing Immunology enterprise. Dr. Bui brings his excellent tumor immunology program to UCSD and the Department of Pathology.

Click here to contact me

Page 'Breadcrumb' Navigation:

External Resources: